Oslo, Norway, February 27, 2006 - Algeta ASA, a therapeutics company dedicated to the development of novel anticancer agents based on alpha particle emitting radionuclides, is pleased to announce that an analysis of the biomarker data from a Phase II trial of its lead product Alpharadin™ (radium-223) continues to demonstrate its potential as a treatment for bone metastases in hormone-refractory prostate cancer (HRPC) patients. Data from this trial (BC1-02) were presented yesterday in a poster (Ref.1) at the 2006 Prostate Cancer Symposium in San Francisco, CA.
